Today's Marketplace (TMP) is proud to announce a featured interview with Acumen Pharmaceuticals (NASDAQ: ABOS) CEO Daniel ...

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US FDA Office of Orphan Products Development (OOPD) has granted ...

ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of ...

Université Clermont Auvergne, Clermont Auvergne INP, CNRS, ICCF, 63000 Clermont-Ferrand, France ...

Investigators released the cause of death for Gene Hackman and his wife Betsy Arakawa on Friday. The New Mexico Office of the Medical Investigator says Hackman died from a cardiovascular disease with ...

Department of Drug Delivery and Molecular Biopharmaceutics, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo 192-0392, Japan ...

BUT WE KNOW THERE’S THESE TOXIC AGGREGATES. THEY’RE CALLED OLIGOMERS. THEY CAN START TO FORM MORE THAN A DECADE BEFORE SYMPTOMS APPEAR AND BEFORE OTHER KNOWN DISEASE MARKERS FORM. THE ABILITY ...

As viral vaccines are increasingly used to meet global health needs, the pharmaceutical industry is manufacturing larger ...

ProMIS Neurosciences (PMN) announced that the Company will present preclinical data on computationally-derived vaccines for neurodegenerative ...

Zervimesine is an investigational oral, once-daily pill being developed for the treatment of CNS diseases, including Alzheimer disease and dementia with Lewy bodies.

Peptide therapeutics, such as GLP-1a (glucagon-like peptide-1 agonists), offer promising treatments for weight control and ...